The Latest Breaking News from Incyte

What to Expect From Incyte’s Next Quarterly Earnings Report

Incyte will report its third-quarter earnings soon, with analysts forecasting a steep triple-digit plunge in its bottom line compared with the year-ago quarter.

Barchart · Oct 9

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.

Barchart · Sep 23

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Aug 18

Incyte Stock: Analyst Estimates & Ratings

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart · May 19

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the

MarketBeat · May 18

Do Wall Street Analysts Like Incyte Corporation Stock?

Wall Street is keeping a confident yet pragmatic stance on Incyte Corporation, supported by steady growth and a promising pipeline.

Barchart · Feb 12

Earnings Preview: What To Expect From Incyte's Report

Incyte is scheduled to release its fourth-quarter results soon, with analysts projecting double-digit surge in its bottom line figure.

Barchart · Jan 13

Is Incyte Stock Outperforming the Nasdaq?

Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart · Dec 15, 2025

Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Sunday revealed new clinical data from two Phase 1 studies of INCA033989 for mutCALR-expressing myeloproliferative neoplasms (MPNs) at the 2025 American Society of Hematology (ASH) Annual Meeting.

Benzinga · Dec 8, 2025

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga · Oct 28, 2025